Mitumomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458284525

| image =

| type = mab

| mab_type = mab

| source = o

| target = GD3 ganglioside

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 216503-58-1

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = KZ9WFQ2NXF

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| IUPHAR_ligand = 7981

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D05061

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.{{cite web|url=http://adisinsight.springer.com/drugs/800003245 |title=Mitumomab - AdisInsight |website=Adisinsight.springer.com |date=2005-06-13 |access-date=2017-01-06}}

The first phase III clinical trial began in 1998.{{ClinicalTrialsGov|NCT00037713|Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG}}{{ClinicalTrialsGov|NCT00006352|Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer}} In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.{{cite journal | vauthors = Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, Rome L, Zatloukal P, Coens C, Giaccone G | display-authors = 6 | title = Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer | journal = European Journal of Cancer | volume = 44 | issue = 15 | pages = 2178–84 | date = October 2008 | pmid = 18676140 | doi = 10.1016/j.ejca.2008.06.036 }}{{cite journal | vauthors = Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C | display-authors = 6 | title = Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) | journal = Journal of Clinical Oncology | volume = 23 | issue = 28 | pages = 6854–64 | date = October 2005 | pmid = 16192577 | doi = 10.1200/JCO.2005.17.186 | doi-access = free }}